Atara Biotherapeutics (ATRA) awards 20,300 RSUs to Chief Accounting Officer
Rhea-AI Filing Summary
Grant-Huerta Yanina reported acquisition or exercise transactions in this Form 4 filing.
Atara Biotherapeutics reported that Chief Accounting Officer Yanina Grant-Huerta received a grant of 20,300 restricted stock units (RSUs) of common stock at no cost. Following this award, she holds 52,050 shares of common stock directly.
The RSUs vest in eight equal installments of one-eighth each. Vesting begins on the second Quarterly Vesting Date after March 9, 2026 and continues on the next seven Quarterly Vesting Dates, subject to her continuous employment. Quarterly Vesting Dates are March 1, May 15, August 15, and November 15, or the first business day thereafter.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 20,300 shares
Net Buy
1 txn
Insider
Grant-Huerta Yanina
Role
Chief Accounting Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 20,300 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 52,050 shares (Direct)
Footnotes (1)
- F1. These restricted stock units ("RSUs") vest as to 1/8th of the total number of shares (rounded down to the next whole number of shares) on the second Quarterly Vesting Date (as defined below) following March 9, 2026, and as to 1/8th of the total number of shares (rounded down to the next whole number of shares) on the next seven Quarterly Vesting Dates, such that all of the shares subject to the RSUs shall be vested on the last Quarterly Vesting Date, subject to the reporting person's continuous employment. "Quarterly Vesting Date" means March 1, May 15, August 15, and November 15 of each year, provided that if such date falls on a weekend or holiday, the Quarterly Vesting Date shall be the first business day after such date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Atara Biotherapeutics (ATRA) report in this Form 4?
Atara Biotherapeutics reported a grant of 20,300 restricted stock units (RSUs) of common stock to its Chief Accounting Officer, Yanina Grant-Huerta. The award is a compensation-related grant, not an open-market purchase or sale, and was received at no cash cost per share.
How many Atara Biotherapeutics RSUs were granted to the Chief Accounting Officer?
The Chief Accounting Officer received 20,300 RSUs of Atara Biotherapeutics common stock. These RSUs represent the right to receive an equivalent number of shares over time, subject to vesting. The grant increases her direct holdings to 52,050 shares after the transaction reported in this filing.
What is the vesting schedule for the 20,300 Atara Biotherapeutics RSUs?
The 20,300 RSUs vest in eight equal installments of one-eighth each. Vesting starts on the second Quarterly Vesting Date after March 9, 2026, then continues on the next seven Quarterly Vesting Dates, provided the reporting person remains continuously employed throughout the vesting period.
How does Atara Biotherapeutics define Quarterly Vesting Dates for these RSUs?
Quarterly Vesting Dates are defined as March 1, May 15, August 15, and November 15 of each year. If any such date falls on a weekend or holiday, the Quarterly Vesting Date shifts to the first business day after that date for vesting purposes.
Were the Atara Biotherapeutics RSUs granted to the CAO issued at a purchase price?
The 20,300 RSUs were granted at a reported price of $0.00 per share. This indicates the award is part of equity-based compensation rather than a cash purchase, with value realized as the RSUs vest into shares over the defined schedule.